SAN FRANCISCO--(BUSINESS WIRE)--Attorney Lexi Hazam of the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP, announced that two patients prescribed olmesartan medoxomil, a ...

(Bloomberg) -- Daiichi Sankyo Inc.’s settlement of thousands of lawsuits blaming the company’s blood-pressure drugs for causing intestinal damage brings to $339 million the amount the drugmaker has ...

Drugmakers Daiichi Sankyo and Forest Laboratories have agreed to a $300 million settlement of multidistrict litigation by users of hypertension drug Benicar who linked their cases of severe diarrhea ...

Bethesda, MD - The US Food and Drug Administration has approved a label change for the angiotensin-receptor blocker (ARB) olmesartan (Benicar, Daiichi Sankyo) to state that the drug can cause an ...

Drugmakers Daiichi Sankyo Co. Ltd. and Forest Laboratories have agreed to a $300 million settlement in multidistrict litigation by users of hypertension drug Benicar who claimed they developed severe ...

BENICAR (olmesartan medoxomil) 5mg, 20mg, 40mg tablets by Daiichi Sankyo The FDA is warning that the antihypertensive Olmesartan Medoxomil can cause intestinal problems known as sprue-like enteropathy ...

Litigation is growing in New Jersey over the blood-pressure drug Benicar, which is alleged to cause intestinal problems leading to chronic diarrhea and dramatic weight loss. Suits pending in state and ...

BETHESDA, Maryland— The US Food and Drug Administration has approved a label change for the angiotensin-receptor blocker (ARB) olmesartan (Benicar, Daiichi Sankyo) to state that the drug can cause an ...